What Kind of Results Have People Seen With Mounjaro®?

How Much Weight Do People Actually Lose on Mounjaro?

Weight loss on tirzepatide is dose-dependent and consistently larger than what has been seen with older GLP-1 medications. SURMOUNT-1 (N=2,539) enrolled adults with a BMI of 30 or higher (or 27 with at least one weight-related comorbidity) who did not have type 2 diabetes. Participants received 5 mg, 10 mg, or 15 mg of tirzepatide weekly for 72 weeks alongside lifestyle counseling.

Mean body weight reductions were 15.0%, 19.5%, and 22.5% for the 5 mg, 10 mg, and 15 mg groups, respectively, compared with 2.5% in the placebo group (SURMOUNT-1, NEJM 2022). That 22.5% figure translates to roughly 52 lb (23.6 kg) for a person starting at 231 lb (105 kg), the trial's mean baseline weight.

Who Loses the Most Weight?

People without type 2 diabetes tend to lose more weight on tirzepatide than those with diabetes. This mirrors the pattern seen with semaglutide and likely reflects the metabolic differences between populations. In SURMOUNT-1, 91% of participants on the 15 mg dose achieved at least 5% weight loss, and 57% achieved at least 20% weight loss (NEJM 2022).

Participants who reached and maintained the 15 mg weekly dose saw the largest reductions. Not everyone titrates to 15 mg. Some patients stay at 10 mg due to gastrointestinal side effects, and their results still outpace many competing agents.

Does Weight Loss Continue Over Time?

Weight loss on tirzepatide is not immediate. Most participants see gradual reductions that accelerate between weeks 12 and 36, then plateau. By week 72, losses were still accruing in some dose groups, suggesting the plateau had not fully arrived for all patients.

The SURMOUNT-4 trial examined what happens when tirzepatide is stopped after 36 weeks of treatment. Participants who switched to placebo regained approximately two-thirds of their lost weight within 88 weeks, while those who continued tirzepatide maintained their losses (SURMOUNT-4, JAMA 2023). Weight regain after stopping is a real pattern, not an anomaly.

What Do Mounjaro Results Look Like for Type 2 Diabetes?

Tirzepatide received its initial FDA approval in May 2022 specifically for glycemic control in adults with type 2 diabetes. The SURPASS clinical program included five phase 3 trials and enrolled over 6,000 participants across different comparator arms.

A1c Reductions in the SURPASS Trials

SURPASS-2 (N=1,879) compared tirzepatide at 5 mg, 10 mg, and 15 mg against semaglutide 1 mg (Ozempic) over 40 weeks. Mean A1c reductions from baseline were 2.01%, 2.24%, and 2.58 percentage points for the three tirzepatide doses, compared with 1.86 percentage points for semaglutide 1 mg (SURPASS-2, NEJM 2021). All three tirzepatide doses achieved superior A1c lowering versus the semaglutide comparator (P<0.001 for all comparisons).

SURPASS-3 (N=1,444) compared tirzepatide against insulin degludec over 52 weeks. The 15 mg tirzepatide group achieved a 2.37 percentage point A1c reduction versus 1.34 percentage points with insulin degludec (SURPASS-3, Lancet 2021).

Weight Loss in the Diabetes Trials

People with type 2 diabetes in SURPASS-2 also lost significant weight. The tirzepatide 15 mg group lost a mean of 11.2 kg (24.7 lb) versus 5.7 kg (12.6 lb) in the semaglutide 1 mg group. This weight loss benefit in a diabetes population was notable and contributed to the FDA's later approval of tirzepatide for chronic weight management under the brand name Zepbound in November 2023 (FDA approval notice).

How Do Mounjaro Results Compare to Ozempic and Wegovy?

The most clinically relevant head-to-head comparison comes from SURPASS-2, which ran tirzepatide directly against semaglutide 1 mg. Tirzepatide at every tested dose produced greater A1c reductions and greater weight loss than semaglutide 1 mg over 40 weeks.

No large randomized trial has yet directly compared tirzepatide to semaglutide 2.4 mg (Wegovy, the obesity-approved dose). Indirect comparisons are possible using published trial data.

Indirect Comparison: SURMOUNT-1 vs. STEP-1

STEP-1 (N=1,961) established semaglutide 2.4 mg's mean weight loss at 14.9% over 68 weeks in adults without diabetes (STEP-1, NEJM 2021). SURMOUNT-1 showed tirzepatide 15 mg producing 22.5% mean weight loss over 72 weeks. These trials used similar but not identical designs, populations, and durations. The difference is large enough that researchers have consistently described tirzepatide as producing greater weight loss in matched populations, though a head-to-head obesity trial remains the definitive test.

The SURPASS-CVOT trial (SURPASS-4, N=2,002) also demonstrated that tirzepatide reduced cardiovascular event risk markers more than insulin glargine in high-risk patients with diabetes over 52 weeks, with the 15 mg group showing a 2.27 percentage point A1c reduction (SURPASS-4, Lancet 2022).

What Side Effects Do People Experience?

Gastrointestinal side effects are the most common reason people reduce their dose or discontinue tirzepatide. The SURMOUNT-1 safety data showed nausea in 31% to 39% of participants across dose groups versus 6% with placebo. Diarrhea occurred in 17% to 23% of the tirzepatide groups, and vomiting in 10% to 14% (SURMOUNT-1, NEJM 2022).

Most side effects were mild to moderate in severity. Severe nausea or vomiting leading to discontinuation occurred in a small percentage of patients.

Managing Side Effects Clinically

Starting at 2.5 mg weekly and titrating every four weeks significantly reduces the burden of gastrointestinal symptoms for most patients. Eating smaller, lower-fat meals during titration also reduces nausea. The prescribing information for Mounjaro specifies the 2.5 mg starting dose solely for tolerability purposes, not for its glycemic or metabolic effect (FDA Mounjaro prescribing information).

Pancreatitis, gallbladder disease, and thyroid C-cell tumors carry boxed or listed warnings in the prescribing information. The thyroid tumor signal comes from rodent studies; human relevance has not been established, but tirzepatide should not be used in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Injection Site Reactions

Injection site reactions (redness, swelling, itching) occur in a small proportion of patients, typically resolving within days. Rotating injection sites between the abdomen, thigh, and upper arm reduces local reactions.

Real-World Mounjaro Results: What Happens Outside of Trials?

Clinical trials control for adherence, coaching, and patient selection in ways that differ from ordinary clinical practice. Real-world data from insurance claims and electronic health records offer a different lens.

Published Real-World Evidence

A 2023 analysis published in Obesity using the Truveta Data Platform examined tirzepatide use in 18,386 adults with obesity in routine clinical settings. Patients who remained on tirzepatide for at least 12 months achieved a mean weight reduction of 15.3%, with those on the highest tolerated dose reaching reductions approaching 20% (Truveta/Obesity 2023). Discontinuation rates at 12 months were approximately 40%, which is lower than typical GLP-1 real-world persistence data but still meaningful.

Patients who discontinued before 6 months lost substantially less weight than those who persisted, reinforcing the clinical value of tolerability management during the early titration phase.

The Role of Lifestyle Coaching

SURMOUNT-1 included lifestyle counseling every four weeks. In real-world practice, the frequency and quality of behavioral support varies. Structured programs that pair tirzepatide with consistent dietary and physical activity coaching appear to produce better outcomes than medication alone, though no large randomized trial has isolated this variable specifically for tirzepatide.

The HealthRX clinical team uses a three-phase framework for patients starting tirzepatide: a tolerability phase (weeks 1 to 12, focus on dose titration and side effect management), a momentum phase (weeks 12 to 36, introducing structured dietary changes as appetite suppression becomes reliable), and a maintenance phase (week 36 onward, with evaluation of whether to continue current dose or consider plateaus). Patients who enter the momentum phase with consistent coaching tend to see better long-term outcomes in practice.

Does Mounjaro Work for People Who Did Not Respond to Other GLP-1s?

Some patients who had limited results on liraglutide (Victoza, Saxenda) or semaglutide (Ozempic, Wegovy) have switched to tirzepatide and seen better outcomes. The dual mechanism (GIP plus GLP-1 receptor agonism) appears to provide additive effects on appetite suppression and glucose metabolism beyond GLP-1 agonism alone.

The GIP Mechanism Difference

GIP (glucose-dependent insulinotropic polypeptide) receptor agonism reduces nausea at pharmacological doses and may increase adipose tissue lipolysis through distinct pathways from GLP-1. A 2023 paper in Cell Metabolism demonstrated that GIP receptor agonism reduces food intake through central nervous system pathways distinct from those activated by GLP-1, potentially explaining why some non-responders to GLP-1 monotherapy respond to tirzepatide (Cell Metabolism 2023).

No randomized trial has specifically enrolled prior GLP-1 non-responders and compared their tirzepatide outcomes to continued GLP-1 therapy. The switch decision remains a clinical judgment based on individual patient history, degree of prior response, and tolerability.

What Do Guidelines Say About Tirzepatide for Weight Management?

The American Association of Clinical Endocrinology (AACE) 2023 clinical practice guidelines on obesity pharmacotherapy list tirzepatide as a first-line option for adults with obesity or overweight with weight-related comorbidities, citing its efficacy data from SURMOUNT-1 and the SURPASS program (AACE Obesity Guidelines 2023). The guidelines state directly: "Tirzepatide produces greater weight loss than any currently approved anti-obesity medication at approved doses."

The American Diabetes Association 2024 Standards of Care in Diabetes recommend tirzepatide as a glucose-lowering agent with evidence for cardiovascular benefit and weight reduction in adults with type 2 diabetes who need additional glycemic control beyond metformin (ADA Standards of Care 2024).

Cardiovascular Outcomes: What Is Known So Far?

Tirzepatide's cardiovascular outcomes trial, SURPASS-CVOT (also called SURPASS-4 in some references), was designed primarily for glycemic comparison rather than as a dedicated cardiovascular outcomes trial. The dedicated cardiovascular outcomes trial for tirzepatide in obesity is the SURMOUNT-MMO trial, which is ongoing as of early 2025.

The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease (SELECT, NEJM 2023). Tirzepatide does not yet have equivalent published cardiovascular outcomes data in an obesity population, though SURMOUNT-MMO is expected to provide this.

What is known: tirzepatide improves several cardiovascular risk markers, including blood pressure, triglycerides, LDL cholesterol, and waist circumference, all of which have established links to cardiovascular event risk (SURPASS-2, NEJM 2021).

What Results Should a New Patient Realistically Expect in the First 3-6 Months?

Most patients do not see large weight changes in the first four to eight weeks. The 2.5 mg starting dose is below the therapeutic weight loss threshold. Meaningful appetite suppression typically becomes noticeable at the 5 mg or 10 mg dose level.

A reasonable expectation for a compliant patient:

• Months 1 to 2 (2.5 to 5 mg): Mild appetite reduction, 1 to 3 kg weight loss, possible GI side effects during titration
• Months 2 to 4 (5 to 10 mg): More consistent appetite suppression, 4 to 8 kg total weight loss for many patients
• Months 4 to 6 (10 to 15 mg if tolerating): Accelerating weight loss, reduction in food cravings, 8 to 15 kg total loss in responsive patients

These figures are approximations derived from the SURMOUNT-1 weight loss curves published in the supplementary data (SURMOUNT-1, NEJM 2022). Individual variation is large.

Patients who achieve less than 5% weight loss after 12 weeks on the highest tolerated dose should have their treatment plan reassessed. The FDA label for Zepbound specifies that healthcare providers should evaluate response after 16 weeks on the 10 mg or 15 mg maintenance dose and consider discontinuation if weight loss is below 5%.